Diabetic patients with non-ST-elevation myocardial infarction represent a group of patients at higher risk of mortality. The lower access to aggressive treatment strategies and suboptimal efficacy of pharmacologic therapies contribute to this inherent risk. This article underscores the importance of providing diabetic patients with more aggressive treatment strategies as well as recent, more effective pharmacologic therapies. J Cardiovasc Med 12:268-269 (C) 2011 Italian Federation of Cardiology.